Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 20/20 | 0.59 |
| ▸ | PARP1 | P09874 | 18/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 18/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.44 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.44 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15568327 | 0.90 | TNKS (0.62) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15567337 | 0.82 | TNKS (0.58) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15568092 | 0.82 | MEN1 (0.61) | TNKSPARP1TNKS2 | |
| SCHEMBL15568341 | 0.82 | TNKS (0.62) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15567220 | 0.78 | TNKS (0.47) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15568942 | 0.77 | TNKS (0.53) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15568640 | 0.76 | TNKS (0.57) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15569103 | 0.76 | TNKS (0.60) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15567497 | 0.76 | TNKS (0.62) | TNKSPARP1TNKS2PARP2PARP3 | |
| SCHEMBL15568371 | 0.76 | TNKS (0.43) | TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882714-B1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | claimed |
| US-9376433-B2 | (AZA-)isoquinolinone derivatives | MERCK PATENT GMBH (DE) | 2016-06-28 | — | — | US | claimed |
| US-20150210686-A1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | claimed |
| EP-2882714-A2 | (AZA-)ISOQUINOLINONE DERIVATIVES | Merck Patent GmbH (DE) | 2015-06-17 | — | — | EP | claimed |
| WO-2014023390-A2 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | claimed |
| EP-2882714-B1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| EP-2882714-B1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| US-9376433-B2 | (AZA-)isoquinolinone derivatives | MERCK PATENT GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-9376433-B2 | (AZA-)isoquinolinone derivatives | MERCK PATENT GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-9376433-B2 | (AZA-)isoquinolinone derivatives | MERCK PATENT GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150210686-A1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210686-A1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210686-A1 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-30 | — | — | US | disclosed |
| EP-2882714-A2 | (AZA-)ISOQUINOLINONE DERIVATIVES | Merck Patent GmbH (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023390-A2 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014023390-A2 | (AZA-)ISOQUINOLINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210686-A1 | (AZA-)ISOQUINOLINONE DERIVATIVES | TANK, TNKS, TDP1 | TNKS 2/4885PARP1 39/4885TNKS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.